Sana Biotechnology's (SANA) "Market Outperform" Rating Reiterated at JMP Securities

Sana Biotechnology (NASDAQ:SANA - Get Free Report)'s stock had its "market outperform" rating restated by investment analysts at JMP Securities in a report released on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. JMP Securities' price objective indicates a potential upside of 76.99% from the stock's previous close.

SANA has been the topic of several other reports. HC Wainwright restated a "buy" rating and set a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. Finally, Citizens Jmp raised shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a research report on Tuesday, March 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $8.60.

Sana Biotechnology Trading Down 1.6%

NASDAQ SANA traded down $0.05 on Tuesday, reaching $2.83. The stock had a trading volume of 2,348,338 shares, compared to its average volume of 3,678,203. Sana Biotechnology has a 1 year low of $1.26 and a 1 year high of $7.40. The business has a 50 day moving average price of $2.17 and a 200 day moving average price of $2.35. The company has a market capitalization of $636.98 million, a price-to-earnings ratio of -3.22 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.02. On average, analysts anticipate that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SANA. Cerity Partners LLC bought a new position in shares of Sana Biotechnology in the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC increased its holdings in Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after purchasing an additional 10,548 shares during the last quarter. Syon Capital LLC bought a new position in Sana Biotechnology during the fourth quarter worth about $27,000. Ameriprise Financial Inc. acquired a new position in shares of Sana Biotechnology during the 4th quarter worth about $29,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Sana Biotechnology in the 1st quarter valued at about $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.